Ames National Corp Takes Position in Stryker Co. (NYSE:SYK)

Ames National Corp bought a new stake in Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 745 shares of the medical technology company's stock, valued at approximately $268,000.

A number of other large investors have also recently bought and sold shares of the business. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker during the 4th quarter worth $25,000. Rakuten Securities Inc. grew its position in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the 4th quarter worth about $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the 4th quarter valued at $33,000. Finally, Activest Wealth Management acquired a new position in shares of Stryker in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Performance

Shares of SYK stock opened at $389.30 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company's fifty day simple moving average is $367.75 and its 200-day simple moving average is $375.89. The firm has a market cap of $148.59 billion, a PE ratio of 50.17, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter last year, the company posted $2.50 earnings per share. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. Equities research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is 45.41%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Evercore ISI reduced their target price on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Finally, Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $427.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.